Efficacy of Apixaban vs. Low Molecular Weight Heparin in Hip Arthroplasty and their Influence on Coagulation Function and Postoperative Deep Vein Thrombosis

This research compared the efficacy of apixaban and low molecular weight heparin in patients undergoing hip arthroplasty and their influence on coagulation function and postoperative deep vein thrombosis. We enrolled 114 patients undergoing hip arthroplasty and assigned them into control group (n=50) and research group (n=64) treated with low molecular weight heparin and apixaban, respectively. The coagulation function which included platelets, prothrombin time, activated partial thromboplastin time, incidence of postoperative deep vein thrombosis, levels of deep vein thrombosis and their associated serum markers like c-reactive protein, d-dimer, homocysteine, and their safety were evaluated and compared between the two groups. The results showed no significant differences in pre- and post-treatment platelets, prothrombin time, activated partial thromboplastin time between research group and control group. The research group was observed with statistically lower postoperative deep vein thrombosis and overall complication rates, as well as lower c-reactive protein, d-dimer and homocysteine levels compared before and after treatment. The results show that although apixaban has no significant effect on blood coagulation in patients undergoing hip arthroplasty. It can effectively prevent postoperative deep vein thrombosis while significantly inhibiting c-reactive protein, d-dimer and homocysteine with fewer adverse reactions.